From the CDMO blog archives: How do CAR T cells fight cancer?

by Stacey Johnson | Sep 8, 2023

In 2019, CCRM launched a new blog to explain products, processes, terms, technologies, techniques and much more related to developing and manufacturing cell and gene therapy products. As a contract development and manufacturing organization (CDMO), CCRM wanted to...

From the CDMO blog archives: Downstream processing

by Stacey Johnson | Aug 28, 2023

In 2019, CCRM launched a new blog to explain products, processes, terms, technologies, techniques and much more related to developing and manufacturing cell and gene therapy products. As a contract development and manufacturing organization (CDMO), CCRM wanted to...

Blog carnival: Challenges and proposed solutions to support a deluge of new CGT approvals

by Stacey Johnson | Aug 22, 2023

It’s exciting news that there are close to 2,000 advanced therapies currently in clinical trials around the world. But is it good news? It’s exciting to see how far the cell and gene therapy (CGT) industry has come and how quickly the pipeline is growing. It’s...

10 days ago in Toronto….

by Michael May | Aug 22, 2023

The 10-year boom of the cell and gene therapy (CGT) industry has inevitably come to an end: public CGT valuations are way down, companies are settling into cash conservation mode, unrealistic salary demands are being replaced by layoffs, and the vultures circling with...

Breaking down barriers between industry and academia to accelerate gene therapy

by David Kent | Aug 22, 2023

As an academic researcher in the blood stem cell field for the last 20 years, I’ve been involved in a large number of interdisciplinary collaborations and, more recently, a series of industry partnerships. There is no doubt in my mind that cell and gene therapy is one...

Translational efficiency will be key for cell and gene therapies entering future markets

by Guest | Aug 22, 2023

Josee Champagne is the co-founder and director of weCANtrial Consulting Group, Inc., a partner of the weCANtranslate Network; Associate Director of Clinical Development at Northern Therapeutics and UC-CISS Program Manager at the Ottawa Hospital Research Institute...

Hope vs hype and champions vs charlatans

by Don Gibbons | Aug 22, 2023

If you are reading all or parts of this blog carnival you are probably a fan of stem cells and regenerative medicine more broadly. You probably believe this field can and will change the way medicine is practiced. But how careful are you when choosing your words to...

For advanced therapies, the sky’s the limit

by Guest | Aug 22, 2023

Phil Vanek is responsible for technical due diligence and evaluation of potential investments, as well as guiding operational, R&D and strategic initiatives carried out at portfolio companies. An entrepreneurial and strategic international business leader, Phil...

Eye on AI: Key takeaways from POLITICO’s sit-down with Peter Marks

by Cal Strode | Aug 16, 2023

In a wide-ranging interview with POLITICO reporter Robert King at the Next Generation of Health Care Therapies event, Dr. Peter Marks, Director, Center for Biologics Evaluation and Research (CBER) at the U.S. Food and Drug Administration (FDA), discussed cell and gene...

Science communication: The skillset our field desperately needs

by Guest | Aug 10, 2023

Ben McLeod has been fascinated by cellular biology since he was 13. He remembers learning that cells are just like miniature cities – with factories, data storage, waste disposal, transportation and communication systems. That fascination drives his work in cell...